, Volume 132, Issue 1, pp 1-4
Date: 22 Sep 2012

Familial prostate cancer and HOXB13 founder mutations: geographic and racial/ethnic variations

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

The use of sequencing in cancer genome studies

Genome-wide association studies (GWAS) have recently made major contributions to the identification of mutations inclusive of G84E in HOXB13 for prostate cancer (Ewing et al. 2012) as featured in this editorial regarding the paper by Xu et al. (2012) published in this issue of the journal. However, along with the contributions of GWAS, there has been the rapid emergence of new technologies dealing with next-generation DNA sequencing (NGS) technology, which are providing unique opportunities to advance this knowledge. Specifically by sequencing the entire genome, entire exome or entire transcriptome, NGS allows an unbiased view to detect genetic defects in familial cancer aggregations as demonstrated by recent cancer genetic/genomic studies (Thompson et al. 2012; Hellebrand et al. 2011).

The exome sequencing method, first developed in 2009, uses the next-generation sequencers to sequence only the exome, that is, the coding part, of the target ...

Invited editorial on Xu et al. (2012).